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Neurodegeneration, a common feature for many brain disorders, has severe
consequences on the mental and physical health of an individual. Typically human
neurodegenerative diseases are devastating illnesses that predominantly affect elderly
people, progress slowly, and lead to disability and premature death; however they
may occur at all ages. Despite extensive research and investments, current therapeutic
interventions against these disorders treat solely the symptoms. Therefore, since the
underlying mechanisms of damage to neurons are similar, in spite of etiology and
background heterogeneous, it will be of interest to identify possible trigger point of
neurodegeneration enabling development of drugs and/or prevention strategies that target
many disorders simultaneously. Among the factors that have been identified so far to
cause neurodegeneration, failures in cholesterol homeostasis are indubitably the best
investigated. The aim of this review is to critically discuss some of the main results
reported in the recent years in this field mainly focusing on the mechanisms that,
by recovering perturbations of cholesterol homeostasis in neuronal cells, may correct
clinically relevant features occurring in different neurodegenerative disorders and, in this
regard, also debate the current potential therapeutic interventions.
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INTRODUCTION: NEURODEGENERATION AND
CHOLESTEROL
Progressive loss of structure or function of neurons, neurodegen-
eration, (Bartzokis, 2004) is a common feature for many neu-
rodegenerative diseases such as Alzheimer’s disease (AD) (Pani
et al., 2009a,b), Parkinson’s disease (PD) (Asher, 2011), multiple
sclerosis (MS) (Luessi et al., 2012), amyotrophic lateral sclero-
sis (ALS) (Pratt et al., 2012) and prion disorders (PrD) (Pani
et al., 2009a,b). Neurodegeneration may also occur in response
to stroke, and head and spinal cord trauma (Thompson, 2008).
Typically these diseases affect older people, however, also autis-
tic spectrum disorders (ASD), which includes autism, attention
deficit disorder (ADD), attention deficit hyperactivity disorder
(ADHD), Asperger syndrome and other disorders that affect
children, are thought to be caused by abnormalities in brain
function or structure of probable genetic origin (Johnson et al.,
2007). Although major advances have been made in the under-
standing neurodegeneration, its pathophysiology is not yet fully
understood and treatment that can prevent or slow down neu-
rodegenerative disorders is still lacking. Therefore, there is an
urgent need to identify possible triggers of neurodegeneration
in order to develop effective treatment and/or prevention strate-
gies that could ameliorate many diseases simultaneously. Among
the factors that until now have been identified as affecting the
neurodegeneration development, failures in cholesterol home-
ostasis are indubitably the most well-known (Anstey et al., 2008;
Christie, 2008). Cholesterol is a multifaceted molecule, which
serves as essential membrane component, as cofactor for signaling
molecules and as precursor for steroid hormones. In the central
nervous system (CNS), it is required for brain growth and myeli-
nation of axons in the developing brain and for continued axon
growth and synapse remodeling in the mature brain (Koudinov
andKoudinova, 2003; Dietschy, 2009). Cholesterol in the CNS has
also an important role in promoting phase separation within neu-
ron membranes leading to laterally organized regions called lipid
rafts (Brown and London, 1998). These regions are enriched in
unesterified (free) cholesterol (FC) and other specific lipid com-
pounds (sphingolipids, plasmenylethanolamine, anionic phos-
pholipids, plasmalogens, and arachidonic acid containing phos-
pholipids) (Simons and Ehehalt, 2002; Korade and Kenworthy,
2008). Lipid rafts allow a lateral separation of the membrane lead-
ing to functionally distinct regions of the membrane. Some lipid
rafts are needed in order to export proteins out of the cell, others
are used to anchor specific proteins in the membrane and keep
protein clusters together. Thus, they are protein and lipid fluctuat-
ing microdomains important for protein trafficking and sorting,
for cell signaling, and for manifold cellular processes. Reduction
of cellular cholesterol leads to disruption of raft functions (Bari
et al., 2005; Murai, 2012). Finally, it is also important to men-
tion the role of cholesterol in the synthesis of neurosteroids.
These compounds act as allosteric modulators of neurotransmit-
ter receptors and are synthesized, especially in myelinating glial
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cells, from cholesterol or steroidal precursors (Mellon andGriffin,
2002; Kimoto et al., 2006). On the basis of the above information,
it can deduce that, changes into one or more of the integrated
sets of homeostatic mechanisms that finely regulate cholesterol
content in neurons, could adversely affect the normal brain func-
tions leading to neurodegeneration; a better understanding of
several molecular mechanisms of cholesterol involvement in this
process might thus represent a useful tool to identify biomark-
ers for neurologic disorders as well as targets for pharmacological
interventions. Here we review some of the main results on the
subject area reported in recent years with the aim to provide plau-
sible explanations of how alterations in brain and blood lipid
metabolism contribute to neurodegeneration. A major focus will
be on the mechanisms that, by restoring cholesterol homeostasis
perturbations in neuronal cells, may improve clinically relevant
features found to be present in different major neurodegenerative
diseases.
CHOLESTEROL IN NEURONAL PLASMA MEMBRANE
The plasma membrane (PM) consists of both lipids and pro-
teins, its fundamental structure being the phospholipid bilayer,
which forms a stable barrier between two aqueous compartments
inside and the outside of the cells. Cholesterol is a ubiquitous
component of all PMs, including those of neurons, where it
determines their permeability, fluidity, and mechanical proper-
ties. In the PMs, cholesterol in its free form has the tendency to
form regularly distributed lateral structures giving rise to the for-
mation of highly ordered nano-scale membrane domains called
lipid rafts (Simons and Ehehalt, 2002; Korade and Kenworthy,
2008) which have important roles in numerous cellular func-
tions. Despite many studies, however, how cholesterol is unique
in promoting the formation of lipid rafts and what emerges from
the interactions of it with other lipids still remain unresolved
questions. It has shown that lipid rafts generally contain 3–5-
fold the amount of cholesterol found in the surrounding bilayer
(Pike, 2003); this cholesterol enrichment seems to be necessary
to hold rafts together and to modulate raft-dependent cell func-
tions, having sterols extraordinary ordering capacity. In neuronal
PMs, FC, due to its structure and the saturation of the hydro-
carbon chains, preferentially interacts with phosphatidylcholines
and sphingolipids such as sphingomyelin; its small head-group
and the rigid ring structure prevent almost all direct sterol-sterol
contacts helping cholesterol to avoid the exposure of hydrophobic
membrane regions to water which would give rise to a very unfa-
vorable contribution to the free energy. The cholesterol biosyn-
thetic pathway shows a systematic removal of methyl groups from
the steroid ring. Each removal step optimizes sterol properties in
terms of ordering and condensing effects (Aittoniemi et al., 2006).
Analysis of the molecular orientations have revealed that choles-
terol, especially at higher concentrations, clearly promotes oppo-
site configurations resulting in a sandwiching-like pattern—two
cholesterol molecules sandwich a phospholipid. This configura-
tion is found to be more likely for saturated than unsaturated
lipids in agreement with cholesterol’s higher tendency to order
and condense saturated than unsaturated lipids, and this may at
least in part explain why the liquid-ordered phase is not observed
at small cholesterol concentrations (Martinez-Seara et al., 2010).
The above discussed organization of cholesterol highlights the
importance of cholesterol’s unique molecular structure in pro-
moting the formation of the liquid-ordered phase. In this spirit
it seems obvious that cholesterol molecules do not function
alone but they do so in a co-operative manner, highlighting the
importance of understanding collective ordering phenomena in
PMs. All these structural and functional roles of cholesterol in
PMs, imply that even minor changes in neuronal PM cholesterol
concentrations can lead to neurodegeneration.
FREE CHOLESTEROL IN THE CENTRAL NERVOUS SYSTEM
Human CNS contains over 23% of the total body cholesterol
while accounting for only 2% of the total body mass. Because
the brain’s cholesterol metabolism is almost exclusively segregated
from the peripheral circulation by the blood brain barrier (BBB),
cholesterol metabolism in brain is different from that in periph-
ery. In the adult brain it is mainly in the FC form and only trace
amount of esterified cholesterol (CE) are present. Nearly 95% of
this FC is synthesized de novo from acetate, predominantly in
the endoplasmic reticulum (ER) of glial cells—astrocytes and, to
a lesser extent, oligodendrocytes—with only small amounts syn-
thesized in neurons (Dietschy and Turley, 2004; Dietschy, 2009).
FC pool in adult human brain (about 490mg/kg) is distributed
among three different compartments: (1) myelin membranes
(2) neuron PMs and (3) glial cells. Myelin membranes account
for 70–80% of FC (about 380mg/kg), whereas the remaining
110mg/kg presumably resides in the membranes of cellular ele-
ments: about 11mg/kg in neurons (∼10% of brain cells), and
about 99mg/kg in different types of glial cells and vascular ele-
ments (Jiménez-López et al., 2010). The specificity of lipids,
mainly FC and their patterns of accumulation during develop-
ment (Dietschy and Turley, 2004; Dietschy, 2009), contributes
to the direct and permissive roles that these compounds play in
signal transduction as well as in both activation and deactiva-
tion of raft resident proteins involved in multiple brain functions
(George and Wu, 2012). The human brain increases dramatically
in size and complexity in the first year of life (Blüml et al., 2012),
and synthesis of lipid components increase in proportion to the
progressive increase of brain volume (Dietschy and Turley, 2004).
From birth to adolescence, there is a 4-fold increase in the volume
of the human brain; this increase however is not uniform: there
is differential growth between subcortical and cortical regions,
and between different regions of cortex. Whereas there is a rapid
increase in synaptogenesis around the time of birth for all corti-
cal areas studied, the most rapid burst of synapse formation and
the peak density of synapses occur at different ages in different
areas (Johnson, 2001). For example, prefrontal cortex is one of
the last regions of the brain to reach maturation, in this region
of brain synaptogenesis starts between 3 and 4 months, and the
density of synapses increases slowly and does not reach its peak
until after the first year. The prefrontal cortex is the part of the
frontal lobes lying just behind the forehead and is responsible
for cognitive analysis and abstract thought, and the moderation
of “correct” behavior in social situations. Although some con-
troversy, the consensus is that brain structures have the overall
appearance of those in the adult by 2 years of age, and that all
the main white matter fiber tracts can be observed by 3 years of
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age (Matsuzawa et al., 2001; Paus et al., 2001). In some reports, it
is suggested that after a rapid increase in grey matter (predomi-
nantly composed of neuron cell bodies and unmyelinated axons),
brain volume up to ∼4 years of age, there is then a prolonged
period of slight decline that extends into adult years (Johnson,
2001). A role for loss of white matter in neurodegeneration has
been previously reported (Bartzokis, 2004), however, whether the
decline in brain volume is associated with loss of white matter
remains unknown (Matsuzawa et al., 2001). It is important to
remember the white matter is so called because the high con-
centration of myelin which is constituted of about 70–85% of
lipids, mainly cerebroside, cholesterol, and phosphatidylcholine.
As cholesterol is an essential component of myelin in white
matter, not surprisingly, the size of the sterol pool in the CNS
increases (or decreases) in a proportional manner to white mat-
ter volume (Dietschy and Turley, 2004). Humans synthesize high
rates of cholesterol after birth mainly in oligodendrocytes, as the
CNS matures and myelin production decreases to very low levels,
CNS cholesterol pool reaches a constant value. In summary, the
majority of brain cholesterol is accumulated between neonatal
period and adolescence when neurons become surrounded by
specialized PMs termed myelin (Dietschy and Turley, 2004). After
myelination, the metabolism of cholesterol in the adult brain is
characterized by a very low turnover and minimal losses (Morell
and Jurevics, 1996). However, recent results indicate that both
cholesterol synthesis and degradation are active in the adult brain
as well and that alterations in these mechanisms profoundly influ-
ence higher-order brain functions (Martin et al., 2010; Orth and
Bellosta, 2012).
CE AND ESTERIFICATION IN THE CNS
As already reported, cholesterol, in adult brain, is mainly in the
free form, while only trace amounts of CE are present. However,
a significant portion (up to 5%) of total cholesterol is found to be
esterified in the developing brain. It follows that the CE concen-
tration in the brain falls between very early stage of development
and late stages of adulthood (Husuf, 1992). Interestingly, a fast
and temporary rise in the concentration of CE occurs at a time
that corresponds to the onset of myelinogenesis. This transient
increase appears to be a universal phenomenon, because it has
been found in all mammalian brains that have been studied so far.
In particular, (Yusuf et al., 1981) reported that in humans the CE
concentrations in the three main parts of brain, forebrain, cere-
bellum, and brainstem, were highest at 13–15 weeks and rapidly
fell during growth. Transient rises in CE concentrations were also
seen around birth in the forebrain and few months after birth in
the cerebellum, a period coinciding with the onset of active myeli-
nation in the respective brain areas. Thus, the increase in the CE
in the developing human forebrain appears to be governed by two
events, one representing brain growth and the other represent-
ing the active phase of myelination, supporting the idea of a close
association between CE and the process of myelination.
Beside during physiologic development, changes in CE
metabolism have been reported in many different neurologic dis-
orders including AD, ALS, MS, and PrD. In particular, an increase
in CE concentration has been found in AD (Puglielli et al., 2001),
MS (Machtoub et al., 2011) and PrD brains (Pani et al., 2011)
and in spinal cords of ALS patients (Cutler et al., 2002). In
animal models it has been found that brain CE accumulation
and increased activity of the esterifying enzyme, acyl coenzyme
A (CoA): cholesterol acyltransferase (ACAT1) precede the clini-
cal phenotype (Posse de Chaves and Narayanaswami, 2008); in
addition, exposure of cultured hippocampal neurons to neuro-
toxic components (i.e., amyloid β-peptide, Aβ) and of cultured
motor neurons to oxidative insults, produces a discrete accumu-
lation of intracellular CE (Cutler et al., 2002). Worthy of mention,
stearoyl-CoA desaturase (SCD), an ER enzyme that catalyzes
the biosynthesis of monounsaturated fatty acids (MUFAs) from
saturated fatty acids has been recently shown to have a role in pro-
viding optimal substrate for cholesterol esterification (Paton and
Ntambi, 2009). This is particularly important in light of the recent
study by Astarita et al. (2011) that suggests that cholesterol/CE
homeostasis (SCD-ACAT) is altered in AD. Although it is still
unclear if elevated levels in CE are the result of cell death process
or if they directly contribute to neurogegeneration, abnormal-
ities in CE metabolism appear to be another characteristic of
neurodegenerative diseases.
FC AND NEURODEGENERATION
Growing evidence indicates that membrane lipid rafts are
involved in the generation of Aβ and PrPsc amyloidogenic-
peptides from amyloid precursor protein (APP) and cellular prion
protein (PrPc), (deposition of which in brain parenchyma and
vessel walls are the major pathological feature of AD and PrD,
respectively), possibly through the creation of a favorable lipid
environment (Figures 1 and 2) (Pani et al., 2011). It has been
reported that, when APP and PrPc molecules occupy a lipid raft
region of the membrane, they are more accessible to and, thus,
preferentially cleaved by amyloidogenic enzymes (i.e., raft resi-
dent β-secretase or BACE1). On the other hand, when APP and
PrPc molecules are outside rafts, they appear to be preferen-
tially cleaved by non-amyloidogenic non-raft resident α-secretase
(ADAM 10) (Simons and Ikonen, 1997). It has been thus sug-
gested that APP and PrPc in the brain are present in two cellular
pools: one, outside rafts, where these two proteins are processed
in a normal way; the other, inside the rafts, where abnormal cleav-
age takes place (Simons and Ikonen, 1997). If it is so, it can
be assumed that compartmentalization of membrane proteins
depends by spatial distribution of the lipid raft microdomains
which in turn is regulated by the levels of FC and therefore that
maintenance of cholesterol homeostasis is essential for neurons. If
cholesterol levels are higher or lower than the physiological range;
several metabolic pathways of compensation can be activated
that if continued for long periods can lead to neurodegeneration
through different mechanisms.
CE AND NEURODEGENERATION
A significant amount of genetic, biochemical, and pharma-
cological data highlighted that modifications in cholesterol
esterification and trafficking are associated with Aβ and PrPsc
biogenesis (Puglielli et al., 2001; Hutter-Paier et al., 2004;
Bhattacharyya and Kovacs, 2010; Huttunen et al., 2010; Pani
et al., 2007a,b,c, 2011; Orrù et al., 2010a,b,c). Moreover, several
studies in various cell and animal models of AD evidenced that,
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FIGURE 1 | Alzheimer’s disease (AD). AD is a progressive neurologic
disease of the brain leading to the irreversible loss of neurons and the loss of
intellectual abilities, including memory, and reasoning, which become severe
enough to impede social or occupational functioning. Although scientists are
still trying to fully understand the cause/s of AD, the formation of amyloid β
(Aβ) protein positive neuritic plaques is considered one of the most important
characteristic of AD so much so that Aβ deposition in the brain is used to
diagnose the disease in autopsy. Aβ peptides are fragments from a larger
protein called amyloid precursor protein (APP), a transmembrane protein that
penetrates through the neuron’s membrane. They are generated in the
amyloidogenic pathway (B) of APP processing by sequential proteolysis by
β- (BACE1) and γ-secretases. In the alternative non-amyloidogenic APP
processing pathway (A), α-secretase cleaves within the Aβ peptide region
and prevents Aβ generation.
genetic or pharmacological inhibition of ACAT activity markedly
suppresses Aβ generation. Inhibition, by RNAi-induced decrease
of ACAT expression, or by ACAT inhibitors (i.e., CP-113,818
and avasimibe), of cholesterol esterification prevents Aβ gener-
ation and its deposition in cell cultures, and markedly reduced
neuritic plaques in AD murine models. More recently, Bryleva
et al. (2010) by using a combined mouse genetic and biochem-
ical approach, showed that ablation of ACAT1 gene in triple
transgenic (3XTg-AD) mice leaded to more than 60% reduction
in full-length human APP and its proteolytic fragments, and to
an improvement in cognitive deficit. Microarray studies during
disease progression of different mouse strain-prion strain com-
binations revealed that ACAT1 expression gene was activated
as early as 10 weeks post prion infection. At advanced stages
of the disease (18–22 weeks after infection), only the ACAT-
encoding gene—out of all the genes involved in cholesterol
synthesis, trafficking, and processing examined—was constantly
up-regulated (Hwang et al., 2009). Changes in cholesterol esteri-
fication similar to that observed in insulted brains were observed
by us in peripheral cells. In particular, increased CE levels were
found in skin fibroblasts and peripheral blood mononuclear cells
(PBMCs) from AD patients and from sheep with natural scrapie
(Pani et al., 2007a,b,c, 2009a,b). It has been shown that about
85% of AD patients displayed significantly higher PBMCs-CE
levels than cognitively normal age-matched controls. Of note
is that parallel analysis in AD first-grade relatives revealed that
up to 30% of them exhibited a peripheral cholesterol pattern
similar to that of AD patients. Interestingly, higher CE pool
was also observed in skin fibroblasts of healthy sheep with a
scrapie susceptible prion genotype compared to sheep carrying
a scrapie-resistant prion genotype (Pani et al., 2007a). In agree-
ment with findings of early ACAT1 activation in mouse brains of
experimental scrapie (Hwang et al., 2009), and in brains of AD
(Pani et al., 2011), we also found increased ACAT1 expression
in both skin fibroblasts and PBMCs from AD patients (Pani
et al., 2009a,b) and in skin fibroblasts from scrapie-affected and
scrapie-susceptible sheep (Pani et al., 2007a).
EVIDENCE FOR ALTERED LIPID HOMEOSTASIS IN AUTISTIC
SPECTRUM DISORDERS (ASD)
Nowadays, more and more researchers talk about ASD as
neurodegenerative disorders (Hagerman, 2006). This is based on
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FIGURE 2 | The prion diseases (PrD). PrD are a large group of related
neurodegenerative conditions, which affect both animals and humans.
Included are Creutzfeldt–Jakob disease and Gerstmann-Strãussler-Scheinker
in humans, bovine spongiform encephalopathy, or “mad cow disease” in
cattle, chronic wasting disease in mule deer and elk, and scrapie in sheep.
Prion diseases are unique in that they can be inherited, can occur
sporadically, or can be infectious. The infectious agent in the PrD is
composed mainly or entirely of an abnormal conformation of a
host-encoded glycoprotein called the prion protein (PrPc). The replication of
prions implies the transformation of the normal version of this protein PrPc
into a misfolded form (PrPsc). An increased concentration of PrPc at the
membrane leads to a structural transition toward abnormal intermolecular
beta sheet. This dimerization could well be the initial step on the pathway
of the conversion into PrPSc.
the identification in some autistic children of pathophysiological
features such as on-going systemic and CNS redox abnormalities
and inflammation, and the evidence of brain volume and neu-
ron loss. Genetic alterations, prenatal exposure to viruses and/or
toxins maternal and fetal immune interactions (Takahashi et al.,
2001; Nicolson et al., 2007), and other as yet undetermined causes
may contribute independently or synergistically to the develop-
ment of autism. Recently, evidence has been reported supporting
a role for cholesterol also in the pathogenesis of these disorders.
Three mechanisms working in concert have been hypothesized
to explain how low cholesterol levels may contribute to spo-
radic ASD (Lee and Tierney, 2011): (1) impaired sonic hedgehog
(SHH) signaling molecules which are involved in the regula-
tion of organogenesis including the organization of the brain.
During embryonic development, SHH is covalently modified
with both palmitate and cholesterol and secreted as part of a
lipoprotein complex that regulates brain morphogenesis through
the patched/smoothened signaling system (2) alterations inmem-
brane lipid raft structure and protein function resulting in abnor-
mal synaptic plasticity, and (3) impaired neurosteroid synthesis.
Starting from these considerations, and from the notion that
many scientists consider AD “nothing more than autism in the
elderly,” we thought that it might be interesting to determine CE
levels in PBMCs from children with sporadic autism. In addition,
since, many studies have outlined the dimensionality of autism
in regard to its comorbidity with other neurodevelopmental dis-
orders such as ADHD we also determined CE levels in PBMCs
from children affected by ADHD. This is the most common psy-
chiatric disorder in children, affecting about 3–5% of children
globally (Spencer et al., 1999) and is characterized primarily by
the co-existence of attention problems and hyperactivity, with
symptoms starting before seven years of age (Waschbusch et al.,
2002; Wilens et al., 2002). In about 30–50% of those individ-
uals diagnosed in childhood, symptoms persist into adulthood
(Kuhne et al., 1997). In a manner similar to that observed in the
AD patients, both autistic and ADHD children unveiled higher
CEs levels in cytoplasm of their PBMCs compared to that of age-
matched control children (Anchisi et al., 2013). These results lead
us to hypothesize that increased intracellular CE levels in PBMCs
might represent a peripheral preclinical and clinical marker of
neurodegeneration both in old and young affected subjects. The
above-mentioned observations leave little doubt that cholesterol
esterification is involved in neurodegeneration and suggest that
CEs and ACAT, beside biomarkers, might become important
therapeutic targets in treating several neurodegenerative disor-
ders. Thus the last part of the review is aimed at providing
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information on the research in the field, whichmay help to under-
stand the molecular mechanism/s underlying the link between
changes in cholesterol esterification and neurodegenerative
processes.
EVIDENCE THAT LOW AND NOT HIGH NEURONAL
MEMBRANE CHOLESTEROL LEVELS CONTRIBUTE TO
NEURODEGENERATION
In spite of the intense research carried out in recent times, the role
of cholesterol as a risk factor for neurodegeneration remains con-
troversial and it is still debated if high or low neuronal membrane
cholesterol levels are involved in neurodegenerative disorders.
In AD, the high cholesterol model assumes that higher FC lev-
els in neuronal membrane may exert harmful effects (Simons
et al., 1998) and implies that lowering CNS cholesterol would
be beneficial to neuronal function. Indeed, there is a large body
of evidence suggesting that increased levels of PM cholesterol
promote the amyloidogenic processing of APP and thereby con-
tribute to the key series of molecular proteolytic events widely
believed to underpin the etiology of AD. A number of genes
involved in cholesterol homeostasis have been identified as sus-
ceptibility loci for sporadic or late-onset AD and cholesterol
and other specific lipids have been also shown to enhance the
propensity of Aβ to form neurotoxic aggregates (Beel et al.,
2010). It has been proposed that high membrane cholesterol
by increasing co-clustering of lipid rafts induces co-localization
of APP-BACE1 (Simons et al., 1998; Wolozin et al., 2000); this
in turn may influence APP processing as well as its location
cleavage stimulating the amyloidogenic pathway that leads to
increased Aβ production. On the contrary, the low membrane
cholesterol model envisages a protective role of relatively high
amounts of membrane cholesterol assuming that APP is located
in non-raft membrane domains (Ledesma andDotti, 2006, 2012).
High membrane cholesterol would maintain APP and BACE1
separated into different membrane domains thus reducing Aβ
generation (Ledesma and Dotti, 2006, 2012; Pani et al., 2011).
The idea that high cholesterol levels might be responsible for neu-
rodegeneration was mainly supported by findings that cultured
human hippocampal neurons and neuroblastoma cells express-
ing the amyloidogenic Swedish mutation of APP, treated with
statins, the well-known inhibitors of cholesterol synthesis, exhib-
ited reduced Aβ production and inflammatory response to Aβ
aggregates and increased α-secretase activity (Höglund et al.,
2006). Statin treatment also contributed to maintain cholesterol
distribution in the cell membrane and normal function of mem-
brane proteins while delaying APP cleavage and Aβ production
(Höglund et al., 2006). Decreased Aβ production has also been
shown in guinea pigs treated with high doses of statins (Ledesma
and Dotti, 2005). However, several new data raise doubts on
the beneficial effects of statins in neurodegeneration and on the
notion that high cholesterol in neuronal membranes is associ-
ated with brain dysfunction. This includes the finding of the
increase of amyloid production and presence of neurodegener-
ation in female mice treated with statins able to cross BBB, the
evidence that defective cholesterol metabolism and trafficking
are present in the familial forms of a number of neurodegen-
erative diseases and the observation that the hippocampus of
certain AD patients present a moderate, yet significant, reduc-
tion in membrane cholesterol (Abad-Rodriguez et al., 2004). As
pointed out above, in neurons, cholesterol inmainly located at the
PMs and membrane environment is of fundamental importance
in regulating membrane protein degradation and in modulating
protein/peptide fibrillization. Actually, cholesterol is crucial for
the myelin as well as for the synapse. Mutant mice lacking the
ability to synthesize cholesterol had severely disturbed myelin in
their brains, and exhibited ataxia (un-coordinated muscle move-
ments) and tremor indicating that cholesterol is an indispensable
component of myelin membranes that contribute proper produc-
tion of the myelin sheath and their function in synapses (Saher
et al., 2005). All these findings call for a reconsideration of the
high cholesterol model, and suggest that low rather than high lev-
els of cholesterol in neuronalmembranes could be detrimental for
cells and might also promote neuronal degeneration. However, it
has been demonstrated that for model cell lines the overall choles-
terol content can change from 2 to 4-fold at different phases of
cell growth (Cansell et al., 1997; Takahashi et al., 2007). Thus, a
full understanding of the in vivo dynamic variability of choles-
terol and lipid raft content in plasma or organelle membranes as
a function of cellular physiological state is still lacking.
MOLECULAR MECHANISMS LINKING CHOLESTEROL
ESTERIFICATION TO NEURODEGENERATION
Taking into account the above and data obtained in our labo-
ratory, a model describing some mechanisms linking cholesterol
esterification to neuronal degeneration could tentatively be pro-
posed (Figures 3 and 4). It is well known that cells and tissues,
including brain, are protected from the accumulation of poten-
tially toxic FC excess by ACAT1–mediated esterification and by
cholesterol efflux (Tabas, 2002), ACAT activity being allosteri-
cally activated by the presence of high FC levels in ER (Chang
et al., 2001). Cellular cholesterol undergoes a continuous cycle
of esterification and ester hydrolysis; net breakdown of CE tak-
ing place when ER–FC levels decline. The enzyme responsible
for the degradation of CE is neutral cholesterol ester hydrolase
(nCEH). Under physiological conditions intracellular CE levels
in brains are very low and generally do not exceed the nCEH
capacity to re-hydrolize CE to FC and to recycle FC back to PM
(Pani and Dessì, 2003). In neurons, if in excess, a part of ER–FC is
converted to CE by ACAT1 located at the ER and stored as cyto-
plasmic lipid droplets, another part leaves the brain (Dietschy,
2009). FC does not across the BBB, therefore before to exit CNS, it
is converted into 24S-hydroxycholesterol (24S-OHC) and in this
form moves from neurons via the ATP-binding cassette trans-
porter A1 (ABCA1) pathway, through cerebrospinal fluid (CSF),
cross the BBB, and is released into the systemic venous circu-
lation. The fate of the 24S-OHC once it reaches the circulation
has not yet been defined. An accurate method based on isotope
dilution-mass spectrometry showed that in blood compartment
24S-OHC is mainly associated with HDL and LDL (Babiker and
Diczfalusy, 1998), suggesting that steady-state plasma 24S-OHC
levels follows the metabolic fate of cholesterol in HDL and LDL
(i.e., uptake by the liver). Since most of the circulating 24S-
OHC arises from brain cholesterol, its levels are considered a
measure of cholesterol turnover in the CNS (Orth and Bellosta,
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FIGURE 3 | Cholesterol homeostasis (steady state). Differently from the
most tissues that take up cholesterol from circulating plasma lipoproteins
through the classic mechanism of the low density lipoprotein receptor (LDLR),
due to the BBB, brain does not have direct access to cholesterol carried by
plasma lipoproteins and therefore, it meets its cholesterol needs through de
novo synthesis mainly in glial cells, with only a small amount of cholesterol
synthesized in neurons. Glial cells package neo-synthesized cholesterol into
Apo E—containing lipoprotein particles, which in turn are secreted into the CSF
through the ATP-binding cassette transporter 1 (ABCA1). Apo E-containing
lipoproteins are then taken up by neurons and FC released is transported for
subsequent metabolism and trafficking to other intracellular sites. Neurons
keep constant their cholesterol concentrations through the same homeostatic
mechanisms regulating the intracellular cholesterol metabolism in peripheral
tissues: cholesterol synthesized in the ER, as well as that released by Apo
E—containing lipoprotein catabolism, moves to PMs, in part, by interacting
with Cav-1. Once the capacity of PMs and other compartments to absorb
cholesterol is exceeded, cholesterol is transported back to the ER, where, in a
small part it is esterified by ACAT and accumulated as lipid droplets. The large
part of excess cholesterol, however, is converted into 24S-OHC, crosses the
BBB, enters the plasma, and is delivered to the liver for excretion into bile.
2012). Cells in the CNS synthesize all of their own cholesterol in
the ER from acetyl CoA through the mevalonate pathway. The
rate-limiting step of the mevalonate pathway is the conversion
of hydroxyl-methyl-glutaryl-CoA (HMG-CoA) to mevalonate by
HMG-CoA reductase. Both these and several other enzymes that
function in later steps of cholesterol synthesis are integral ER
membrane proteins. In the ER, FC levels fluctuate much more
than that in PMs and are considered the major regulators of the
cellular cholesterol homeostatic machinery. Once synthesized, FC
leaves the ER, thereby helping to maintain low ER sterol content
and is rapidly targeted to PMs where, depending on the type of
CNS cells is utilized for membrane turnover and axonal growth
or become available for extracellular apoprotein E (Apo E) accep-
tors (astrocytes) (Dietschy, 2009; Orth and Bellosta, 2012). In
summary, the ER, where many critical enzymatic reactions of
cholesterol metabolism take place, is relatively cholesterol poor,
thus maintenance of cellular cholesterol homeostasis necessitates
the transport of cholesterol between subcellular membranes and
PMs and eventually its exchange with Apo E and/or ABCA1 for
efflux. These findings imply that an imbalance of one or more of
these finely regulated homeostatic mechanisms capable of causing
even modest changes in ER–FC pool, may contribute to serious
and sometimes fatal conditions. In this way, it is plausible to sup-
pose that, if a reduction in the transport of cholesterol between
ER and PMs occurs as a consequence of genetic and/or environ-
mental factors, ER–FC in neurons may increase. This increase
activates ACAT1 leading to abnormal CE accumulation while
membrane cholesterol and its distribution in raft-domains are
reduced. If this altered transport persists over time the conse-
quences will be: rafts disassembly, demyelination, alterations in
synapsis formation and function (neurodegenerative disorders).
Considering that caveolin-1 (Cav-1) is a cholesterol-binding pro-
tein that delivers newly synthesized cholesterol at the ER to the
PMs (Smart et al., 1996), the fact that embryonic fibroblasts
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FIGURE 4 | Cholesterol homeostasis (neurodegenerative disorders).
An imbalance of one or more of finely regulated homeostatic
mechanisms that lead to even modest changes in ER-FC pool in
neurons can cause a serious and sometimes fatal neurologic disorder.
Namely, if a reduction in the transport of cholesterol between ER and
PM occurs as a consequence of genetic and/or environmental factors,
neuronal ER-FC increases. This increase may cause the activation
of ACAT1 leading to an increased CE synthesis while reducing the
distribution of FC in raft-domains. If these alterations persist over time
the consequences may be: rafts disassembly, demyelination, alterations
in synapse formation and function, in other words, neurodegeneration.
Beside ACAT1 activation, an increase in ER cholesterol pool of neurons
may also activate the CYP46A1 thereby enhancing the levels of
circulating 24S-OHC. This is an oxygenated derivative of cholesterol able
to cause lipoprotein oxidation (ox-LP). With a mechanism similar to that
described for atherosclerosis, o×-Lp might be recognized by scavenger
receptors (SR) on the surface of white blood cells, which in turn may
be engorged with CE and become foam cells.
and peritoneal macrophages from Cav-1 null mice were found
enriched in CEs but depleted of FC membranes compared with
their wild-type counterparts (Chang et al., 2006), supports these
conclusions. Signs of premature neuronal aging and degenera-
tion, increased Aβ, decreased cerebrovascular volume and reduc-
tion in synapses were also observed in brains of young Cav-1 null
mice compared to young WT mice (Head et al., 2010). Very low
mRNA levels of Cav-1 and particularly nCEH were found by us in
skin fibroblasts and in PBMCs from patients with AD (Pani et al.,
2009a,b). Interestingly, neuron-targeted re-expression of Cav-1 in
Cav-1 null neurons in vitro decreased Aβ expression (Head et al.,
2010).
Beside ACAT1 activation, an increase in ER cholesterol pool
of neurons may activate the enzyme cholesterol 24-hydroxylase
(CYP46A1) thereby enhancing production of 24S-OHC (Shafaati
et al., 2007). The oxysterol is then secreted into CSF, and
through the BBB, delivered into the circulation. Really, ele-
vated CSF-24S-OHC concentrations have been found in patients
with AD compared to age-matched controls (Prasanthi et al.,
2009), this elevation was even more pronounced in CSF of
moderate cognitive decline—mild or early stage of AD in which
an increase of 24S-OHC was also consistently observed in the
plasma compartment. In plasma, 24S-OHC is mainly present
in HDL and LDL in its esterified form (24S-OHCE). At this
point, it should be mentioned that 24S-OHC is an oxygenated
derivative of cholesterol and consequently a potential inducer
of LDL oxidation. In agreement increased levels of circulating
oxidized LDL (ox-LDL) were found in patients with neuro-
logic disorders (Ehnholm, 2009). With a mechanism similar
to that described for atherosclerosis, ox-LDL might be recog-
nized by scavenger receptors (SR) on the surface of white blood
cells, which in turn may be engorged with CE. Such a sce-
nario may help to explain why subjects with neurological disor-
ders frequently present an accumulation of CE in their PBMCs.
According to this model, progressive FC accumulation in ER
membranes would intensify ACAT1 dysfunction leading to neu-
rodegeneration. Finally, efflux pathways may also be inhibited
by conversion of cholesterol into oxysterols. This information
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indicates that brain cholesterol alterations during neurodegener-
ation involve dynamic modifications in cholesterol homeostatic
networks, which are reflected in peripheral tissues, therefore, the
use of therapeutic strategies, aimed at re-establishing right choles-
terol membrane amounts and their differential distribution in
lipid rafts, would contribute to successful treatment/prevention
of neurodegenerative disorders.
CE AS DRUG TARGET FOR PREVENTION AND/OR
TREATMENT OF NEURODEGENERATION
In previous studies we have found that cell treatments with com-
binations of various cholesterol interfering drugs showed synergic
anti-prion effects, apparently by restoring cholesterol homeosta-
sis in infected cells (Orrù et al., 2010c) The lysosomotropic
drugs quinacrine and chlorpromazine, which, in addition to
several other effects (Dohura et al., 2000) respectively deter-
mine cell cholesterol redistribution (Klingenstein et al., 2006)
and activation of cholesterol biosynthesis (Fernø et al., 2006),
transportation and efflux (Vik-Mo et al., 2009), reduced up
to 10-fold their EC50 against PrPsc when associated with a
CE inhibitor (Varghese et al., 2005), or with the cholesterol-
trafficking modulators such as progesterone or verapamil (Butler
et al., 1992; Debry et al., 1997). CE levels directly correlate with
Aβ production (Bhattacharyya and Kovacs, 2010), as already
mentioned, in fact, experiments in cellular and animal mod-
els of AD showed dramatic reduction of Aβ generation and
deposition upon inhibition of ACAT. Interestingly, a report on
Aβ-positive neurons of autopsied brain tissue from AD patient
not only showed the presence of lipid droplets in neurons, but
also showed a positive correlation between Aβ levels and lipid
droplets (Gomez-Ramos and Asuncion Moran, 2007). Although,
at present, it is not possible to form a complete picture of
the functionally relevant causal relations, ACAT1 has becom-
ing an excellent potential drug target for neurodegeneration.
Inhibition of ACAT1 reduces the intracellular CE and storage,
leaves more FC available for the membrane compartment and
causes a decrease in Aβ production (Bhattacharyya and Kovacs,
2010).
The knowledge of the critical role played by ACAT in the for-
mation of CE-enriched cells (foam cells), the accumulation of
which has an integral part into the development of atheroma,
led to the discovery of several inhibitors of this enzyme (Chang
et al., 2009). Theoretically, inhibition of ACAT, by blocking the
esterification of cholesterol, could prevent the transformation
of macrophages into foam cells and slow the progression of
atherosclerosis. In some animal models, ACAT inhibitors were
remarkably effective in reducing the formation of atheromas
(Bocan et al., 1993; Kusunoki et al., 2001), however, no indi-
cation of whether this effect was due to a reduction in the
number of cells or to the extent of CE enrichment or to both
was reported. On the contrary, some studies involving geneti-
cally engineeredmice have suggested that the inhibition of ACAT1
may promote atherosclerosis (Perrey et al., 2001). In addition,
recent clinical trials of ACAT inhibitors in humans failed to
show a therapeutic efficacy and this prompted researchers to
pronounce the imminent death of ACAT inhibitors as a viable
anti-atherosclerotic therapy (Farese, 2006). ACAT inhibitors are
currently not marketed and more research is needed to develop
safe and effective inhibitors for human use. In 2008, a study
used the mammalian target of rapamycin (mTOR) inhibitor,
rapamycin, to treat learning disabilities associated with a dis-
ease called tuberous sclerosis complex (TSC) in mice (Ehninger
et al., 2008). This is a rare genetic disorder that causes brain
tumors, seizures, learning disabilities, skin lesions, and kid-
ney tumors. In humans, half of TSC patients are autistic.
The results showed that rapamycin was able to reverse mental
retardation in TSC mice raising the possibility that this drug
may be effective in the treatment of mental disorders asso-
ciated with autism (Ehninger et al., 2008). In 2010, Galvan
and her team published a research showing that rapamycin
also improves learning and memory deficits and reduces brain
lesions and Aβ levels, in a mouse model of AD, suggesting
that rapamycin may have an another exciting use: to fight AD
(Spilman et al., 2010). Rapamycin added to diet late in life
was also able to extend lifespan in a mice model of aging
(Harrison et al., 2009). If these results continue to be repeated
and pilot studies demonstrate that treatment works and is safe,
rapamycin, which is already approved for other indications,
could be utilized—sooner than expected—to prevent behavioral
symptoms in autistic children and in AD patients as well as
to improve health to the end of life. At this point it will be
crucial to understand how rapamycin exerts its positive effect
on the brain. It has been suggested that the drug operates
in preventing behavioral symptoms in autism and AD and in
extending lifespan through a combination of anti-neoplastic
effects and effects on cellular stress resistance and response to
nutrient dynamics. In a study that has just been published, it
has been shown that the levels of three major monoamines
(norepinephrine, dopamine and 5-hydroxytryptamine) and their
metabolites (3,4-dihydroxyphenylacetic acid, homovanillic acid,
and 5-hydroxyindolacetic acid) were significantly increased in
midbrain of rapamycin-treated mice compared to controls.
The Authors suggest that oral administration of rapamycin,
enhances learning and memory in young adults, maintains
memory in old C57BL/6J mice, and has concomitant anxi-
olytic and antidepressant-like effects, possibly by stimulating
major monoamine pathways in brain (Halloran et al., 2012).
Studies conducted to evaluate the effect of rapamycin in the
human coronary artery smooth muscle cell (VSMC) showed
that besides its effect as mTOR inhibitor, rapamycin amelio-
rated imbalance of intracellular cholesterol homeostasis induced
by inflammatory cytokines. In particular, in VSMCs, the drug
reduced lipid droplets accumulation and CE content induced by
IL-1 and increased intracellular cholesterol efflux by upregulat-
ing ABCA1 and ABCG1 gene expression. Similar results were also
obtained in our laboratories in peripheral cells from AD patients
(Pani et al., 2009a; Mulas et al., 2011). When everolimus, the
40-O-(2-hydroxyethyl) derivative of sirolimus, was added to cul-
tured fibroblasts obtained by skin biopsy from AD patients, a sig-
nificant reduction of CE accumulation was observed (Pani et al.,
2009a). In prion-infected N2a cells, Nile red and filipin stain-
ing of intracellular lipids reveals changes both in the content and
distribution of most intracellular lipids; cell treatments with CE
modulators, showed marked anti-prion activity. The most potent
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anti-prionic effect was obtained with everolimus that drasti-
cally inhibited cholesterol esterification. Anti-prion effect also
had verapamil, a calcium-blocking drug that inhibits cholesterol
trafficking from the PM to the ER, and progesterone, a
sterol hormone that affects cholesterol trafficking both from
the PM and lysosomes (Orrù et al., 2010c). These results
suggest that inhibitors of cholesterol esterification by restor-
ing cholesterol homeostasis may represent a more successful
therapeutic approach than drug treatments lowering choles-
terol content per se (i.e., statins). Notably, our data also
point to CE accumulation in peripheral cells as an easy-
to-detect hallmark associated with neurodegenerative disor-
ders and/or indicative of increased susceptibility to develop
disease.
CONCLUSION
In this reviewwe present evidence that preexistent and/or induced
modifications of cholesterol homeostasis may create a mem-
brane lipid environment favorable to the initiation/progression
of neurodegeneration, and therefore that pharmacologic retrieval
of these modifications may represent a successful way to hamper
neuronal degeneration. Even if there is still much to be learned
about the physiologic function of cholesterol esterification and its
precise role in polarized cells such as neurons, CE and ACAT1
appear to be suitable targets for anti-neurodegeneration drug
development. In this context, drugs able to reduce the rate of
cholesterol esterification, such as ACAT inhibitors, progesterone
and rapamycin in particular, are emerging as the best suited for
this purpose.
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